Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
Anifrolumab shows higher remission rates versus placebo in SLE patients regardless of immunosuppressant history
A New Lupus Drug May Work Better If You Start It Sooner
A post hoc analysis of pooled Phase 3 RCT data in 726 patients with moderate-to-severe SLE found higher DORIS remission rates with anifrolum…
Starting a new lupus drug before trying older medications may help patients reach remission faster and with fewer side effects.
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.